Amanda Schiefer, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1477563104
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,181 of the $204,101 with a category attached, or 85.8%. Novo Nordisk accounts for 92.0% of it on its own, with 38 other manufacturers making up the rest.
Across 531 payments — averaging $384.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$188K
- Lilly USA, LLC$12K
- Insulet Corporation$520
- AstraZeneca$449
- Amgen$431
- Boehringer Ingelheim$418
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$175,18186%
- Travel & lodging$17,2138%
- Food & beverage$11,6956%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 227 | $187,797 |
| Lilly USA, LLC | 68 | $11,726 |
| Insulet Corporation | 27 | $520 |
| AstraZeneca | 21 | $449 |
| Amgen(2 entities) | 27 | $431 |
| Boehringer Ingelheim | 14 | $418 |
| Bayer | 16 | $357 |
| Corcept Therapeutics | 11 | $266 |
| Dexcom, Inc. | 10 | $210 |
| Medtronic(2 entities) | 10 | $198 |
| Abbott | 10 | $171 |
| Pfizer | 11 | $166 |
| Esperion Therapeutics, Inc. | 8 | $159 |
| AbbVie | 9 | $153 |
| Merck | 9 | $151 |
| Novartis | 8 | $144 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| Valeritas, Inc. | 3 | $76 |
| Tandem Diabetes Care, Inc. | 5 | $69 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Astellas Pharma US Inc | 3 | $53 |
| Amryt Pharma Holdings Ltd | 2 | $47 |
| Zealand Pharma US, Inc. | 3 | $40 |
| Lifescan, Inc. | 2 | $32 |
| IBSA Pharma Inc. | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Embecta Corp. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| BD | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
| BETA Bionics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$204,101 in reported general payments places this provider in the 85th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 516 | $699,485 |
| MounjaroTirzepatide | 218 | $313,860 |
| Tresiba Flextouch U-200Insulin Degludec | 214 | $209,968 |
| JardianceEmpagliflozin | 178 | $179,055 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 131 | $177,644 |
| FarxigaDapagliflozin Propanediol | 108 | $99,996 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 71 | $61,322 |
| SynthroidLevothyroxine Sodium | 631 | $50,500 |
| TrulicityDulaglutide | 40 | $44,812 |
| Repatha SureclickEvolocumab | 54 | $41,134 |
| Novolog FlexpenInsulin Aspart | 130 | $34,957 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $29,607 |
| NovologInsulin Aspart | 90 | $28,633 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $19,775 |
| RybelsusSemaglutide | 20 | $18,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog, Rybelsus | $187,797 | $924,341757 claims |
| Lilly USA, LLCMounjaro, Trulicity | $11,726 | $358,672258 claims |
| Boehringer IngelheimJardiance | $418 | $179,055178 claims |
| AstraZenecaFarxiga | $449 | $99,996108 claims |
| AbbVieSynthroid | $153 | $50,500631 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $110 | $13,54319 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $10,8031,264 claims |
| MerckJanuvia | $151 | $8,10313 claims |
| IBSA Pharma Inc.Tirosint | $32 | $3,16624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
- Christina GloverJackson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.